This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/022417-2023

Contract

Decision Support Services

GENOMICS ENGLAND LIMITED

F03: Contract award notice

Notice identifier: 2023/S 000-022417

Procurement identifier (OCID): ocds-h6vhtk-03ec49

Published 2 August 2023, 10:58am

Section I: Contracting authority

I.1) Name and addresses

GENOMICS ENGLAND LIMITED

Level 21, One Canada Square

LONDON

E14 5AB

Contact

Procurement Team

Email

procurement@genomicsengland.co.uk

Telephone

+44 8082819535

Country

United Kingdom

Region code

UKI43 - Haringey and Islington

Companies House

08493132

Internet address(es)

Main address

www.genomicsengland.co.uk

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Decision Support Services

II.1.2) Main CPV code

• 48814400 - Clinical information system

II.1.3) Type of contract

Supplies

II.1.4) Short description

Extension of current provision of interpretation services for the NHS Genomic Medicine Service

In November 2018 Genomics England signed a contract with Congenica for the provision of interpretation services to support the soon to be implemented NHS Genomic Medicine Service ("GMS") ("Decision Support Contract") which is due to expire on 31 July 2023.

Genomics England has on 31 July 2023 entered into an amendment to the Decision Support Contract under which Congenica will be provide the services for a further period of 16 months with an option to extend for a further 6 months.

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. A new procurement will

require preparation and proper planning to meet the future objectives of the service yet to be agreed with NHS England.

In the event that this were to be considered a new contract award, Genomics England consider that Regulation 32 (2) (b) of the Public Contract Regulations 2015 would apply in any event for the same reasons. There is no other product available in the market to meet the immediate need and requirements and Congenica holds the IP rights to the product. Any supplier would need to substantially develop its standard product to fit Genomics England's needs. This would include customising release cycles to fit the needs of NHS England. Congenica's version of Congenica Rare Disease for Genomics England is a very specific product developed for a single customer. For this reason, there is no genuine competition for the Genomics England version of Congenica Rare Disease on the market today and time will be required for Genomics England to plan its future requirements.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £4,500,000

II.2) Description

II.2.3) Place of performance

NUTS codes

UKH - East of England

II.2.4) Description of the procurement

GMS interpretation services

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: <u>2017/S 212-440597</u>

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

31 July 2023

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Congenica Ltd

Cambridge

Country

United Kingdom

NUTS code

• UKH - East of England

Companies House

08273616

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £4,500,000

Section VI. Complementary information

VI.3) Additional information

In November 2018 Genomics England signed a contract with Congenica for the provision of interpretation services to support the soon to be implemented NHS Genomic Medicine Service ("GMS") ("Decision Support Contract") which is due to expire on 31 July 2023.

Genomics England has on 31 July 2023 entered into an amendment to the Decision Support Contract under which Congenica will be provide the services for a further period of 16 months with an option to extend for a further 6 months.

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. A new procurement will require preparation and proper planning to meet the future objectives of the service yet to be agreed with NHS England.

In the event that this were to be considered a new contract award, Genomics England consider that Regulation 32 (2) (b) of the Public Contract Regulations 2015 would apply in any event for the same reasons. There is no other product available in the market to meet the immediate need and requirements and Congenica holds the IP rights to the product. Any supplier would need to substantially develop its standard product to fit Genomics England's needs. This would include customising release cycles to fit the needs of NHS England. Congenica's version of Congenica Rare Disease for Genomics England is a very specific product developed for a single customer. For this reason, there is no genuine competition for the Genomics England version of Congenica Rare Disease on the market today and time will be required for Genomics England to plan its future requirements.

VI.4) Procedures for review

VI.4.1) Review body

Genomics England

London

Country

United Kingdom